Lobbyists for brand drug makers have told Senate Finance Committee staff they’re open to paying a share of seniors’ catastrophic Medicare Part D drug costs in exchange for capping seniors’ out-of-pocket costs and relieving drug makers of the 70% discounts they currently must pay for drugs that beneficiaries take while in the donut hole, according to sources close to the negotiations. Finance members are using a Part D reform proposal by the American Action Forum as a template for changes...